FDA & Diagnostic Innovators Unite to Provide Update on Precision Medicine Initiative at CHI's Eighth Annual Next Generation Dx Summit

A Plenary Session at the 2016 Next Generation Dx Summit in Washington, DC Will Set the Stage for Knowledge-Sharing to Enhance Patient Care Through National-Level Research and Technology Innovation

NEEDHAM, MA--(Marketwired - May 17, 2016) -  Cambridge Healthtech Institute is pleased to release the plenary session details for the eighth annual Next Generation Dx Summit to be held August 23-26, 2016 at the Grand Hyatt, Washington, DC. FDA's Personalized Medicine Director, Elizabeth Mansfield, will open the session with an update on the FDA's implementation of more targeted studies involving patient's specific genetics, health history and lifestyle. In the second part of the plenary session, diagnostic innovators will join to present game-changing technologies in the industry and case studies on incorporating them into laboratory medicine.

"When Vice President Biden announced his plans for a 'moonshot' to cure cancer this past January in Davos, Switzerland, it brought into question whether or not the backing needed for advanced sequencing and other disruptive technologies will happen," states Christina Lingham, Cambridge Healthtech Institute's Conference Executive Director. "The plenary session at Next Generation Dx Summit will showcase the cross-industry support for the mission: the FDA's active participation in more targeted therapies, and the diagnostics teams creating the technologies needed to make precision medicine a reality."

Complementing the plenary session at the Next Generation Dx Summit is a lineup of focused conference tracks, symposia and interactive courses, covering the key challenges in the field: novel immunotherapy biomarkers, cell-free DNA, companion diagnostics, infectious disease, point-of-care, pharmacy-based diagnostics, commercialization, and reimbursement. New programming in 2016 will greatly expand the scope of the event with coverage of prenatal diagnostics, circulating tumor cells, forensics, telemedicine, microbiome sequencing, health and wellness genomic screening and digital PCR. A brand new area of the event will explore the area of hospital laboratory design and renovation that is undergoing significant transformation with emerging diagnostics technologies.

Full program details can be found at http://www.nextgenerationdx.com. Early registration rates apply and are available until June 10.

Members of the media are encouraged to attend. Please contact Lisa Scimemi at lscimemi@healthtech.com to apply for a press pass and to inquire about opportunities for coordinated pre-event interviews with speaking faculty.

About Cambridge Healthtech Institute (www.healthtech.com)

Cambridge Healthtech Institute (CHI), a division of Cambridge Innovation Institute, is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech, CROs, academia, and niche service providers. CHI is renowned for its vast conference portfolio held worldwide including PepTalk, Molecular Medicine Tri-Conference, SCOPE Summit, Bio-IT World Conference & Expo, PEGS Summit, Drug Discovery Chemistry, Biomarker World Congress, World Preclinical Congress, Next Generation Dx Summit and Discovery on Target. CHI's portfolio of products include Cambridge Healthtech Institute Conferences, Barnett International, Insight Pharma Reports, Cambridge Marketing Consultants, Cambridge Meeting Planners, Knowledge Foundation, Bio-IT World, Clinical Informatics News and Diagnostics World.

Contact Information:

Lisa Scimemi
Corporate Marketing Communications Director